The market is estimated to grow with a CAGR of 8.1% from 2018-2025.
Pancreatic Cancer Therapy Market Insight
According to The Insight Partners market research study titled ‘Pancreatic Cancer Therapy Market - Global Analysis and Forecasts By Type, Therapy, the global pancreatic cancer therapy market is expected to reach US$ 4,056.4 Mn in 2025 from US$ 2,011.2 Mn in 2017. The market is estimated to grow with a CAGR of 8.1% from 2018-2025. The report highlights the trends prevalent in the global pancreatic cancer therapy market and the factors driving the market along with those that act as deterrents to its growth.
Pancreatic cancer begins when the cells in the pancreas grow uncontrollably. Based on the type of cell affected, pancreatic cancer can be classified into two types, exocrine tumors, and endocrine tumors. These tumors behave differently. Hence they are treated differently. Pancreatic cancer generally diagnosed at a later stage since the symptoms are not easily detected or diagnosed. Factors such as chronic inflammation of the pancreas (pancreatitis), diabetes, smoking, and obesity are some of the identified causes of pancreatic cancer. The pancreatic cancer therapy market growth is attributed to factors such as rise in number of patients suffering with pancreatic cancer, increasing healthcare expenditures for pancreatic drugs and increase in number of therapies launched in the market. Additionally, development of efficient therapy for pancreatic cancer treatment is expected to stimulate the market during the forecast period. However, side effects of the therapies and low success rate of treatments are expected to restrain the market of pancreatic cancer therapy.
Get sample Research on Pancreatic Cancer Therapy Market study at: https://www.theinsightpartners.com/sample/TIPMD00002009/
Pancreatic Cancer Therapy Market Comparative Landscape and Key Development
The major players operating in the pancreatic cancer therapy market include Eli Lilly and Company, F. Hoffmann-La Roche AG, Celgene Corporation, Amgen Inc., Novartis AG, Pharmacyte Biotech Inc., Clovis Oncology, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Merck & Co., Inc. among others. For instance, in May 2018, Eli Lilly and Company acquired AMRO BioSciences. AMRO BioSciences is engaged into number of drugs for cancer. The clinical trial explores a drug (pegilodecakin) which is ongoing for the pancreatic cancer. The drug is into phase III of the clinical trials. The developments performed by the companies are helping the market to grow in the coming years.
Rise in Number of Patients Suffering with Pancreatic Cancer
Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. Pancreatic cancer is the 12th most commonly occurring cancer in the world. According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of death related to cancer in the US and is expected to be the second leading cause of death by 2020. According to Cancer Research UK, approximately 9,921 new cases of pancreatic cancer were diagnosed in the UK in 2015, while 8,912 patients died due to same cancer. The cancer is almost always fatal and thus demands potential therapies for the patients’ treatment. For instance, the American Cancer Society suggests that pancreatic cancer accounts for approximately 3% of deaths of all cancers in the US.
According to the National Institute of Health, an estimated of 68,615 patients in 2015 were living with pancreatic cancer in the US. The increasing incidence and prevalence of pancreatic cancer are expected to increase the demand for drugs, therapies, and treatment of patients. Moreover, the rising number of patients results in advancements in molecular biology and chemical drug formulation. Thus, a huge pool of patients who have pancreatic cancer is expected to increase the growth of the global pancreatic cancer therapy market over the forecast years.
Type Insights
Based on type, the pancreatic cancer therapy market is segmented into endocrine pancreatic cancer and exocrine pancreatic cancer. In 2017, the exocrine pancreatic cancer segment held the largest share of the market, by type. The exocrine pancreatic cancer segment is expected to grow at the fastest rate during the coming years as this type of cancer is the most common and majorly occurring type and thus is expected to have massive patient pool over the forecast years.
Based on therapy, the pancreatic cancer therapy market is segmented into biologic therapy, chemotherapy, and others. In 2017, biologic therapy segment held the largest share of the market, by therapy. Moreover, the biologic therapy segment is expected to grow at the fastest rate during the coming years owing to increasing number of novel upcoming immunotherapies as well as targeted cell therapy that treats the cancer without any severe side effects and has number of therapeutic benefits over the conventional chemotherapies.
Buy Complete Report of Pancreatic Cancer Therapy Market Study at: https://www.theinsightpartners.com/buy/TIPMD00002009/
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
E-mail: sam@theinsightpartners.com